MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis

Marjon, Katya, Cameron, Michael J., Quang, Phong, Clasquin, Michelle F., Mandley, Everton, Kunii, Kaiko, McVay, Michael, Choe, Sung +9 more·2016·Cell Reports

DOI 10.1016/j.celrep.2016.03.043

Cited by (499)

Items 201–300 of 499

MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer
Fadi E. Pulous, Barbara Steurer, Frank W. Pun, Man Zhang, Feng Ren, Alex A. Zhavoronkov · 2024 · Drug Discovery Today
Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective
Raluca Andrada Munteanu, Ciprian Tomuleasa, Cristina Adela Iuga, Diana Gulei, Tudor–Eliade Ciuleanu · 2023 · Cancers
Biliary tract cancer prognostic and predictive genomics
Sebastián Mondaca, Bruno Nervi, Mauricio P. Pinto, Ghassan K. Abou‐Alfa · 2019 · Chinese Clinical Oncology
SYVN1-MTR4-MAT2A Signaling Axis Regulates Methionine Metabolism in Glioma Cells
Lude Wang, Bin Hu, Kailing Pan, Jie Chang, Xiaoya Zhao, Lin Chen, Haiping Lin, Jing Wang, Gezhi Zhou, Wenxia Xu et al. · 2021 · Frontiers in Cell and Developmental Biology
PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression
Weiwei Yan, Xun Liu, Xuefeng Qiu, Xuebin Zhang, Jiahui Chen, Kai Xiao, Ping Wu, Chao Peng, Xiaolin Hu, Zengming Wang et al. · 2024 · Journal of Clinical Investigation
Current landscape of targeted therapy in esophageal squamous cell carcinoma
Amane Jubashi, Daisuke Kotani, Takashi Kojima, Naoko Takebe, Kohei Shitara · 2024 · Current Problems in Cancer
Epigenetic Regulation of Fanconi Anemia Genes Implicates PRMT5 Blockage as a Strategy for Tumor Chemosensitization
Changzheng Du, Steven W. Li, Simranjit X. Singh, Kristen Roso, Michael A. Sun, Christopher J. Pirozzi, Rui Yang, Jian-Liang Li, Yiping He · 2021 · Molecular Cancer Research
A germinal center–associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL
Kohta Miyawaki, Koji Kato, Takeshi Sugio, Kensuke Sasaki, Hiroaki Miyoshi, Yuichiro Semba, Yoshikane Kikushige, Yasuo Mori, Yuya Kunisaki, Hiromi Iwasaki et al. · 2021 · Blood Advances
Deletion ofMTAPHighly Sensitizes Osteosarcoma Cells to Methionine Restriction With Recombinant Methioninase
YUSUKE AOKI, Yasunori Tome, Qinghong Han, Jun Yamamoto, Kazuyuki Hamada, NORIYUKI MASAKI, Yutaro Kubota, Michael Bouvet, Kotaro Nishida, Robert M. Hoffman · 2022 · Cancer Genomics & Proteomics
Diagnostic and Therapeutic Perspectives Associated to Cobalamin-Dependent Metabolism and Transcobalamins’ Synthesis in Solid Cancers
Valentin Lacombe, Guy Lenaers, G. Urbanski · 2022 · Nutrients
Fragment optimization and elaboration strategies – the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits
Christopher R. Smith, Svitlana Kulyk, Misbha Ud Din Ahmad, Valentina Arkhipova, James G. Christensen, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon E. Kuehler, J. David Lawson et al. · 2022 · RSC Medicinal Chemistry
Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase
Rajesh K. Harijan, Oskar Hoff, Rodrigo Gay Ducati, Ross Firestone, Brett M. Hirsch, Gary B. Evans, Vern L. Schramm, Peter C. Tyler · 2019 · Journal of Medicinal Chemistry
Essential genes shape cancer genomes through linear limitation of homozygous deletions
Maroulio Pertesi, Ludvig Ekdahl, Angelica A. Palm, Ellinor Johnsson, Linnea Järvstråt, Anna-Karin Wihlborg, Björn Nilsson · 2019 · Communications Biology
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
M.M. Gounder, Patricia Martín-Romano, Antoîne Italiano, L. L. Siu, Philippe Alexandre Cassier, Gerald Steven Falchook, Izidore S. Lossos, Drew Warren Rasco, J.F. Hilton, Meredith Ann McKean et al. · 2025 · Annals of Oncology
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors
Christopher R. Smith, Ruth Aranda, James G. Christensen, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon E. Kuehler, J. David Lawson, Matthew A. Marx et al. · 2022 · Bioorganic & Medicinal Chemistry
The Rio1 protein kinases/ATPases: conserved regulators of growth, division, and genomic stability
Giovanna Berto, Sébastien Ferreira-Cerca, Peter De Wulf · 2018 · Current Genetics
Protein arginine methylation in transcription and epigenetic regulation
Hoang Quoc Hai Pham, Xiaoqun Tao, Yanzhong Yang · 2023 · Frontiers in Epigenetics and Epigenomics
Mechanism and Inhibition of Human Methionine Adenosyltransferase 2A
Courtney N. Niland, Agnidipta Ghosh, Sean M. Cahill, Vern L. Schramm · 2021 · Biochemistry
Human Mat2A Uses an Ordered Kinetic Mechanism and Is Stabilized but Not Regulated by Mat2B
Jonathan Bailey, Holly L. Douglas, Laura Masino, Luiz Pedro S. de Carvalho, Argyrides Argyrou · 2021 · Biochemistry
Reduced symmetric dimethylation stabilizes vimentin and promotes metastasis in MTAP‐deficient lung cancer
Wen‐Hsin Chang, Yi‐Ju Chen, Yi‐Jing Hsiao, Ching-Cheng Chiang, Chia‐Yu Wang, Ya‐Ling Chang, Qi‐Sheng Hong, Shr‐Uen Lin, Shr‐Uen Lin, Gee‐Chen Chang et al. · 2022 · EMBO Reports
Magnetic-Driven Hydrogel Microrobots Selectively Enhance Synthetic Lethality in MTAP-Deleted Osteosarcoma
Haoran Mu, Chenlu Liu, Qi Zhang, Huanliang Meng, Shimin Yu, Ke Zeng, Jing Han, Xinmeng Jin, Shi Shi, Peiyao Yu et al. · 2022 · Frontiers in Bioengineering and Biotechnology
A patent review of MAT2a inhibitors (2018–2021)
Stephen J. Atkinson, Laura Evans, James S. Scott · 2022 · Expert Opinion on Therapeutic Patents
The cytologic diagnosis of mesothelioma: are we there yet?
Claire W. Michael · 2022 · Journal of the American Society of Cytopathology
Scalable Atroposelective Synthesis of MRTX1719: An Inhibitor of the PRMT5/MTA Complex
Michał Achmatowicz, Thomas Scattolin, David R. Snead, Dinesh J. Paymode, Sahar Roshandel, Chen Xie, Guihui Chen, Cheng‐yi Chen · 2023 · Organic Process Research & Development
The diagnostic utility of methylthioadenosine phosphorylase immunohistochemistry for pancreatic ductal adenocarcinoma in FNA and small biopsy specimens
Sanhong Yu, Leona A. Doyle, Jason L. Hornick, Jeffrey K. Mito · 2023 · Cancer Cytopathology
Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2
Jessica M. Posada, Evgeny Yakirevich, Ashish M. Kamat, Akshay Sood, Joseph M Jacob, Gennady Bratslavsky, Petros D. Grivas, Philippe E. Spiess, Roger Li, Andrea Necchi et al. · 2024 · Modern Pathology
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers
Gianluca Mauri, Giorgio Patelli, Laura Roazzi, Emanuele Valtorta, Alessio Amatu, Giovanna Marrapese, Erica Francesca Bonazzina, Federica Tosi, Katia Bruna Bencardino, Gabriele Ciarlo et al. · 2024 · Journal of Clinical Pathology
Development of a Series of Pyrrolopyridone MAT2A Inhibitors
Stephen J. Atkinson, Sharan K. Bagal, Argyrides Argyrou, Sean Askin, Tony Cheung, Elisabetta Chiarparin, Muireann Coen, Iain T. Collie, Ian L. Dale, Claudia De Fusco et al. · 2024 · Journal of Medicinal Chemistry
The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma
Tanner Wright, Yalong Wang, Mark T. Bedford · 2021 · Epigenomes
Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction
Xin Zhao, Bin Liu, William N. William, Kaloyan M. Tsanov, Yu-Jui Ho, Francisco M. Barriga, Raymond J. Lim, Maria Trifas, Azhar Khandekar, Yushen Du et al. · 2024 · Journal of Thoracic Oncology
Load and lock: An emerging class of therapeutics that influence macromolecular dissociation
Raymond J. Deshaies, Patrick Ryan Potts · 2025 · Science
Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science
Darrin D. Stuart, Angel Guzman-Perez, Natasja Brooijmans, Erica L. Jackson, Gregory V. Kryukov, Adam A. Friedman, Axel Hoos · 2023 · Cancer Discovery
Transition state analogue of MTAP extends lifespan of APCMin/+ mice
Ross Firestone, Mu Feng, Indranil Basu, Karina Peregrina, Leonard H. Augenlicht, Vern L. Schramm · 2021 · Scientific Reports
Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma
Tatjana Vlajnic, Obinna Chijioke, Luca Roma, Spasenija Savic Prince, Tobias Zellweger, Cyrill A. Rentsch, Lukas Bubendorf · 2024 · Modern Pathology
Microbial metabolites in tumor epigenetic regulation
Wangzheqi Zhang, Haoling Zhang, Yan Liao, Shuya Jiang, Haolong Zhang, Chenwei Huang, ZhiJing Song, Rui Zhao, Ping Lü, Xiaohong Kang et al. · 2026 · iMeta
Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss
Maroun Bou Zerdan, Prashanth Ashok Kumar, Elio Haroun, Nimisha Srivastava, Jeffrey S. Ross, Abirami Sivapiragasam · 2023 · Oncotarget
The RioK1 network determines p53 activity at multiple levels
Michela Damizia, Gian Mario Moretta, Peter De Wulf · 2023 · Cell Death Discovery
A role for RIO kinases in the crosshair of cancer research and therapy
Morteza Ghandadi, Albert L. Dobi, Sanjay V. Malhotra · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer
Alessia Cacciatore, Dheeraj A. Shinde, Carola Musumeci, Giada Sandrini, Luca Guarrera, Domenico Albino, Gianluca Civenni, Elisa Storelli, Simone Mosole, Elisa Federici et al. · 2024 · Nature Communications
Deletion and downregulation of MTAP contribute to the motility of esophageal squamous carcinoma cells
Xiao-Yu Cheng, Zou Liu, Shang Li, Hong‐Qing Cai, Yu Zhang, Yan Cai, Xin Xu, Jia‐Jie Hao, Ming‐Rong Wang · 2017 · OncoTargets and Therapy
RIOK1 kinase activity is required for cell survival irrespective ofMTAPstatus
Alexandra Hörmann, Barbara Hopfgartner, Thomas Köcher, Maja Corcokovic, Teresa Krammer, Christoph Reiser, Gerd Bader, Junwei Shi, Katharina Ehrenhöfer, Simon Wöhrle et al. · 2018 · Oncotarget
The International System for Reporting Serous Fluid Cytopathology—An Updated Review
Minhua Wang, Ashish Chandra, Guoping Cai · 2023 · Journal of Clinical and Translational Pathology
SCR‐7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S‐adenosylmethionine‐competitive or the methylthioadenosine‐cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase‐deleted tumors
Zhiyong Yu, Yi Kuang, Liting Xue, Xuan Ma, Tingting Li, Linlin Yuan, Mengying Li, Grace Xue, Zhen Li, Feng Shii Tang et al. · 2024 · MedComm
Discovery of 2(1H)-Quinoxalinone Derivatives as Potent and Selective MAT2A Inhibitors for the Treatment of MTAP-Deficient Cancers
Chunzheng Li, Xiaojing Lan, Xinge Li, Yixian Fu, Gang Gui, Xiaodong Li, Yanyan Shen, Zhenjie Gan, Min Huang, Xiaoming Zha · 2025 · Journal of Medicinal Chemistry
Biomedical effects of protein arginine methyltransferase inhibitors
Mengtong Cao, Terry Nguyen, Jiabao Song, Yujun George Zheng · 2025 · Journal of Biological Chemistry
Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates
Binbin Cheng, Zongbao Ding, Yimeng Hong, Yaping Wang, Yingxing Zhou, Jianjun Chen, Xiaopeng Peng, Chunlai Zeng · 2025 · European Journal of Medicinal Chemistry
PRMT5 inhibitors: Therapeutic potential in pancreatic cancer
Carolin Schneider, Valentina Spielmann, Christian Joerg Braun, Günter Schneider · 2025 · Translational Oncology
The catalytic efficiency of METTL16 affects cellular processes by governing the intracellular S-adenosylmethionine setpoint
Juliana N Flaherty, Enakshi Sivasudhan, Matthew Tegowski, Xing Zheng, Madeline M. McGinnis, Olga V. Hunter, Kyah M. Featherston, Komal Sethia, Benjamin P. Tu, Kate D. Meyer et al. · 2025 · Cell Reports
Expression and localisation of methylthioadenosine phosphorylase (MTAP) in oral squamous cell carcinoma and their significance in epithelial-to-mesenchymal transition
Yusuke Amano, Daisuke Matsubara, Atsushi Kihara, Hiroshi Nishino, Yoshiyuki Mori, Toshiro Niki · 2021 · Pathology
Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models
Zuoyu Jiang, Xuetao Li, Zongyu Xiao, Wenjuan Gan, Xuewen Zhang, Yang Zhang, Weichao Wang, E Qinzhi, Yu Huang, Qikun Shi et al. · 2025 · Cell Death Discovery
CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP -Deleted Cancer
Nikola Knoll, Sarah Masser, Blanka Bordas, Richard Y. Ebright, Guangyan Li, Devishi Kesar, Eliana Destefanis, Nicholas Kania, Diego J. Rodriguez, Jayu Jen et al. · 2025 · Cancer Research
Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance
Junyan Li, Liyuan Zhang, Yan Shang, Juan Liu, Hailong Zhao · 2026 · Clinical and Translational Medicine
Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs
Yajing Du, Lulu Luo, Xinru Xu, Xinbing Yang, Xueni Yang, Shizheng Xiong, Jiafeng Yu, Tingming Liang, Li Guo · 2023 · Pharmaceutics
Identification of a Sonically Activated Degrader of Methionine Adenosyltransferase 2A by an in Silico Approach Assisted with the Hole–Electron Analysis
Huan He, Ziwei Wang, Xueke Peng, Luolong Qing, Yu Zhang, Shaojuan Fu, Juan Xu, Yuanyuan Li, Silong Zhang · 2024 · Journal of Medicinal Chemistry
Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity
Meng Zhang, Xiaoyu Ding, Zhongying Cao, Yilin Yang, Xiao Ding, Xin Cai, Man Zhang, Alexander M. Aliper, Feng Ren, Hongfu Lu et al. · 2025 · Journal of Medicinal Chemistry
A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem
Benjamin J. McLean, Aji Istadi, Teleri Clack, Mezzalina Vankan, Daniel Schramek, G. Gregory Neely, Marina Pajic · 2022 · Advanced Genetics
Resistance to PRMT5-targeted therapy in mantle cell lymphoma
Mackenzie Long, Shirsha Koirala, Shelby L. Sloan, Fiona Brown-Burke, Christoph Weigel, Lynda Villagomez, Kara N. Corps, Archisha Sharma, Ian Hout, Margaret Harper et al. · 2023 · Blood Advances
Continuous Fluorescence Assays for Reactions Involving Adenine
Ross Firestone, Scott A. Cameron, Peter C. Tyler, Rodrigo Gay Ducati, Adam Z. Spitz, Vern L. Schramm · 2016 · Analytical Chemistry
MTAP deficiency confers resistance to cytosolic nucleic acid sensing and STING agonists
Jung-Mao Hsu, Chunxiao Liu, Weiya Xia, Chung‐Yu Chen, Wei‐Chung Cheng, Junwei Hou, Mien‐Chie Hung · 2025 · Science
Distinct mechanisms of PTEN inactivation in dogs and humans highlight convergent molecular events that drive cell division in the pathogenesis of osteosarcoma
Aaron L. Sarver, Lauren J. Mills, Kelly M. Makielski, Nuri A. Temiz, Jinhua Wang, Logan G. Spector, Subbaya Subramanian, Jaime F. Modiano · 2023 · Cancer Genetics
An Unanticipated Modulation of Cyclin-Dependent Kinase Inhibitors: The Role of Long Non-Coding RNAs
Debora Bencivenga, Emanuela Stampone, Angela Vastante, Myassar Barahmeh, Fulvio Della Ragione, Adriana Borriello · 2022 · Cells
Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
A. van Dalen, J Favier, L Baumgartner, Ute Hasholzner, Hwa de Bruijn, D Dobbler, V H Dombi, D. Fink, Maurizia Giai, Peter G. McGing et al. · 1999 · PubMed
Long read sequencing reveals a novel class of structural aberrations in cancers: identification and characterization of cancerous local amplifications
Yoshitaka Sakamoto, Liu Xu, Masahide Seki, Toshiyuki Yokoyama, Masahiro Kasahara, Yukie Kashima, Akihiro Ohashi, Yoko Shimada, Noriko Motoi, Katsuya Tsuchihara et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
RNA Splicing as a Therapeutic Target in Cancer
Alexander M. Lewis, Kenyon Weis, Omar Ibrahim Abdel-Wahab · 2025 · The Annual Review of Pharmacology and Toxicology
Systemic Therapy for Advanced Biliary Tract Cancers in 2026: Current Standard of Care and Emerging Therapeutic Strategies
Hyunseok Yoon, Changhoon Yoo · 2025 · Journal of Gastroenterology and Hepatology
Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities
Yoonae Jeong, Yena Cho, Yong Kee Kim · 2026 · Journal of Biomedical Science
De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R. Cole, Apoorva Uboveja, Richard S. Fang, Amandine Amalric, Baixue Yang, Adam G. Chatoff et al. · 2024 · Cancer Research Communications
Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma
Stefano Lucà, Giovanna Pignata, Alessandro Cioce, Cecilia Salzillo, Rossella De Cecio, Gerardo Ferrara, Carminia Maria Della Corte, Floriana Morgillo, Alfonso Fiorelli, Marco Montella et al. · 2025 · Cancers
Methionine cycle inhibition disrupts antioxidant metabolism and reduces glioblastoma cell survival
Emma C. Rowland, Matthew D’Antuono, Anna M. Jermakowicz, Nagi G. Ayad · 2025 · Journal of Biological Chemistry
Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression
Neshat Nilforoushan, Neda A. Moatamed · 2020 · Annals of Diagnostic Pathology
Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy
Enyu Lin, Ping Zhu, Chujin Ye, ManLi Huang, Xuechao Liu, Kaiwen Tian, Yanlin Tang, Jiayi Zeng, Shouyu Cheng, Jiumin Liu et al. · 2022 · Frontiers in Immunology
Extracellular 5′-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins
Baiqing Tang, Hyung‐Ok Lee, Sapna Gupta, Liqun Wang, Alison Kurimchak, James S. Duncan, Warren D. Kruger · 2022 · Journal of Biological Chemistry
Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening
Tuomo Kalliokoski, Henna Kettunen, Esa T. T. Kumpulainen, Emilia Kettunen, Gabriel Thieulin‐Pardo, Lars Neumann, Maren Thomsen, Ralf Paul, Alina Malyutina, Μαρία Γεωργιάδου · 2023 · Bioorganic & Medicinal Chemistry Letters
Functional genomics screening identifies aspartyl‐ tRNA synthetase as a novel prognostic marker and a therapeutic target for gastric cancers
Bin Liu, Hiroto Katoh, Daisuke Komura, Asami Yamamoto, Mieko Ochi, Takumi Onoyama, Hiroyuki Abé, Tetsuo Ushiku, Yasuyuki Seto, Jian Suo et al. · 2022 · The Journal of Pathology
Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma
Taketo Kato, Ichidai Tanaka, Heng Huang, Shoji Okado, Yoshito Imamura, Yuji Nomata, Hirofumi Takenaka, Hiroki Watanabe, Yuta Kawasumi, Keita Nakanishi et al. · 2025 · International Journal of Molecular Sciences
PRMT5: A Promising Synthetical Lethal Target for MTAP-Deleted Cancers
Bang Li, Jin-Qi Yu, Zhenjiao Yang, Yuanxiang Wang · 2025 · Journal of Medicinal Chemistry
CysMP reveals metal ion–specific metalloproteomes and copper-regulated PGK1 activity in glycolysis
Yamei Yuan, Zhiyuan Wang, Chenfang Si, Jianlong Li, Fandong Ren, Yi Yuan, Zi‐Qi Shi, Nana Sun, Xiaonuo Ma, Xingbang Dai et al. · 2025 · Science Advances
MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies
Mihaela D. Aldea, Sean M. Lenahan, Marie-Anaïs Locquet, L. Liao, M. Gasparro, P.C. Gokhale, Maria‐Rosa Ghigna, D.N. Ionescu, Igor Odintsov, Kenneth H. Ngo et al. · 2026 · Annals of Oncology
Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss
Michael F. Basin, Gennady Bratslavsky, Nathan Nahhas, Alina Basnet, Hanan Goldberg, Andrea Necchi, Ethan S. Sokol, Shakti H Ramkissoon, Richard S.P. Huang, Jeffrey S. Ross et al. · 2022 · Urologic Oncology Seminars and Original Investigations
Discovery of Potent and Oral Bioavailable MAT2A Inhibitors for the Treatment of MTAP-Deleted Tumors
Qun Li, Yang Zang, Dan An, Lifei Liu, Wen Jiang, Rongchen Liu, Jiangtao Su, Jun Jie Yang, Lie Li, Xuejun Zhang · 2023 · ACS Medicinal Chemistry Letters
Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer
Elisa Mariella, Gaia Grasso, Martina Miotto, Kristi Buzo, Nicole Megan Reilly, Pietro Andrei, Pietro Paolo Vitiello, Giovanni Crisafulli, Sabrina Arena, Giuseppe Rospo et al. · 2024 · Molecular Oncology
Functional genomic exploration reveals that Ss-RIOK-1 is essential for the development and survival of Strongyloides stercoralis larvae
Yuan Wang, Huan Zhou, James B. Lok, Weiqiang Lei, Siyuan He, Robin B. Gasser, Rui Zhou, Rui Fang, Yanqin Zhou, Junlong Zhao et al. · 2017 · International Journal for Parasitology
Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens
Sumana Srivatsa, Hesam Montazeri, Gaia Bianco, Mairene Coto‐Llerena, Charlotte K.Y. Ng, Salvatore Piscuoglio, Niko Beerenwinkel · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
Application and research progress of synthetic lethality in the development of anticancer therapeutic drugs
Xiaoliang Gong, Chunxi Liu, Haoyang Tang, Song Wu, Qingyun Yang · 2024 · Frontiers in Oncology
Identification of New Genetic Clusters in Glioblastoma Multiforme: EGFR Status and ADD3 Losses Influence Prognosis
Lara Navarro, Teresa San‐Miguel, Javier Megías, Núria Santonja, Silvia Calabuig Fariñas, Lisandra Muñoz Hidalgo, Pedro Roldán, Miguel Cerdá‐Nicolás, Concha López‐Ginés · 2020 · Cells
Analysis of the error surface of the XOR network with two hidden nodes
Len Hamey · 1996
Asymmetric and symmetric protein arginine methylation in methionine-addicted human cancer cells
Ashley G. Holtz, Troy L. Lowe, YUSUKE AOKI, Yutaro Kubota, Robert M. Hoffman, Steven Gerard Clarke · 2023 · PLoS ONE
Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways
Jodie Bojko, Madhu Kollareddy, Marianna Szemes, Jacob Bellamy, Evon Poon, Ahmad Moukachar, Danny Legge, Emma E. Vincent, Nicholas Jones, Sally Malik et al. · 2024 · Cancer Letters
High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer
Harun Öztürk, Fidan Seker-Polat, Neda Abbaszadeh, Yasemin Kingham, Sandra Oršulić, Mazhar Adli · 2025 · Journal of Clinical Investigation
Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications
Bárbara Bueloni, Maite G. Fernández‐Barrena, Esteban Juan Fiore, Matias Antonio Avila, Juan Bayo, Guillermo Daniel Mazzolini · 2025 · Gut
Clinical Actionability of Genes in Gastrointestinal Tumors
Nadia Saoudi Gonzalez, Giorgio Patelli, Giovanni Crisafulli · 2025 · Genes
Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer
Youwen Zhu, Kun Liu, Hong Zhu · 2026 · Experimental Hematology and Oncology
Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop
Xiangyu Zeng, Fei Zhao, Xinyi Tu, Yong Zhang, Wen‐Bin Yang, Jing Hou, Qi Jiang, Shouhai Zhu, Zheming Wu, Yalan Hao et al. · 2025 · Journal of Clinical Investigation
Exploiting binding-site arginines in drug design: Recent examples
Hong Lin, Juan I. Luengo · 2020 · Bioorganic & Medicinal Chemistry Letters
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression
Sara Busacca, Qi Zhang, Annabel Jane Sharkey, Alan G. Dawson, David Allan Moore, David A. Waller, Apostolos Nakas, Carolyn Jones, Kelvin Cain, Jinli Luo et al. · 2021 · Scientific Reports
Functional analysis of 3′-UTR hairpins supports a two-tiered model for posttranscriptional regulation ofMAT2Aby METTL16
Olga V. Hunter, Julio Cesar Ruiz, Juliana N Flaherty, Nicholas K. Conrad · 2023 · RNA
Discovery of a first-in-class inhibitor of the PRMT5-substrate adaptor interaction
David C. McKinney, Brian J. McMillan, Matthew J. Ranaghan, Jamie A. Moroco, Merissa Brousseau, Zachary Mullin-Bernstein, Meghan O’Keefe, Patrick R. McCarren, Michael F. Mesleh, Kathleen M. Mulvaney et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
MicroRNA‑21‑5p expression in extracellular vesicles is increased in the blood of aging mice and in vascular endothelial cells induced by ionizing radiation
Keisuke Yamamoto, Mitsuru Chiba · 2024 · Experimental and Therapeutic Medicine
The Tumor Metabolite 5′-Deoxy-5′Methylthioadenosine (MTA) Inhibits Maturation and T Cell-Stimulating Capacity of Dendritic Cells
Christina Brummer, Katrin Singer, Frederik C. Henrich, Katrin Peter, Carolin Dorothea Strobl, Bernadette Neueder, Christina Bruß, Kathrin Renner, Tobias Pukrop, Wolfgang Herr et al. · 2024 · Cells
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial
Maria‐Veronica Teleanu, Christoph E. Heilig, Sebastian Pirmann, Rainer Hamacher, Sebastian Bauer, Verena I. Gaidzik, R. Mayer-Steinacker, Jude Al-Sabah, Sandra S.L. Roldan Pinzon, H. Süße et al. · 2025 · ESMO Open